医学
临床试验
重症监护医学
背景(考古学)
临床研究设计
疾病
全身疗法
临床终点
人口
内科学
乳腺癌
癌症
环境卫生
古生物学
生物
作者
Maria Dall’Era,David Wofsy
出处
期刊:Current Opinion in Rheumatology
[Ovid Technologies (Wolters Kluwer)]
日期:2006-09-01
卷期号:18 (5): 476-480
被引量:11
标识
DOI:10.1097/01.bor.0000240357.22680.63
摘要
Purpose of review The purpose of this review is to discuss the challenges inherent in the design of clinical trials for patients with systemic lupus erythematosus. Recent findings Recent years have witnessed a renewed interest in the conduct of systemic lupus erythematosus clinical trials. Three key design decisions play particularly critical roles in determining the fate of these trials: selection of the study population from among patients with very heterogeneous disease manifestations; selection of the treatment and control regimens; and selection of the primary endpoint. Four recent randomized, controlled trials dealt with these decisions in the context of a variety of interventions, including new biologic agents, hormonal therapies, and anti-metabolites. These trials are informative about the implications of each approach. Summary Systemic lupus erythematosus investigators are faced with substantial trial design challenges because of the inherently complex nature of this disease. The hope is that lessons learned from prior and ongoing trials will inform future trial design such that the efficacy of new agents can be determined and new therapies will become available for patients with SLE.
科研通智能强力驱动
Strongly Powered by AbleSci AI